SCHEMBL6901269

SCHEMBL6901269

O=C(NCCc1ccccc1)Nc1ncc(Br)cn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.53
EPHX1 P07099 3/20 0.53
RAB9A P51151 4/20 0.52
NPC1 O15118 3/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
CNR1 P21554 1/20 0.52
HDAC1 Q13547 2/20 0.52
HDAC2 Q92769 2/20 0.52
ROCK2 O75116 3/20 0.51
ROCK1 Q13464 2/20 0.51
ATG4B Q9Y4P1 1/20 0.51
HDAC3 O15379 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
KDM4E B2RXH2 2/20 0.49
POLB P06746 1/20 0.49
APOBEC3A P31941 1/20 0.49
HSD17B10 Q99714 1/20 0.49
PRMT3 O60678 1/20 0.49
TRPV1 Q8NER1 1/20 0.49
MAPT P10636 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6906194 0.83 ALDH1A1 (0.72) ALDH1A1EPHX1RAB9ANPC1SMN1; SMN2
SCHEMBL6905303 0.83 ALDH1A1 (0.71) ALDH1A1RAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL6901408 0.81 NPC1 (0.51) ALDH1A1EPHX1RAB9ANPC1SMN1; SMN2
SCHEMBL4897395 0.78 CNR1 (0.74) ALDH1A1EPHX1RAB9ANPC1SMN1; SMN2
SCHEMBL26686613 0.77 MAPK1 (0.52) ALDH1A1EPHX1RAB9ANPC1SMN1; SMN2
SCHEMBL20495335 0.77 HDAC3 (0.63) ALDH1A1RAB9ANPC1HDAC1HDAC2
SCHEMBL1932276 0.76 MAPK1 (0.64) ALDH1A1RAB9ANPC1SMN1; SMN2ROCK2
SCHEMBL6032606 0.76 EPHX1 (0.85) ALDH1A1EPHX1RAB9ANPC1SMN1; SMN2
SCHEMBL1932994 0.76 AURKB (0.65) ALDH1A1EPHX1RAB9ANPC1SMN1; SMN2
SCHEMBL4606056 0.75 EPHX1 (0.81) ALDH1A1EPHX1RAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040116418-A1 Compounds and methods for inhibition of HIV and related viruses MEDIVIR AB (SE) 2004-06-17 US disclosed
US-20020132794-A1 Compounds and methods for inhibition of HIV and related viruses MEDIVIR AB 2002-09-19 US disclosed
US-6376492-B1 GUANIDINE DERIVATIVES MEDIVIR AB (SE) 2002-04-23 US disclosed
US-5849769-A N-arylalkyl-N-heteroarylurea and guandine compounds and methods of treating HIV infection MEDIVIR AB (SE) 1998-12-15 US disclosed
EP-0706514-B1 COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES MEDIVIR AB (SE) 1998-11-18 EP disclosed
EP-0706514-A1 COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES MEDIVIR AB (SE) 1996-04-17 EP disclosed
WO-1995006034-A1 COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES MEDIVIR AB (SE) 1995-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020132794-A1 Compounds and methods for inhibition of HIV and related viruses POLRMT, POLM, POLR1E ALDH1A1 2484/4885EPHX1 1892/4885RAB9A 3313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.